Author:
Lu Hui,Xiao Juanjuan,Ke Changshu,Ni Xiaofang,Xiu Ruijuan,Tian Qin,Pan Huaxiong,Zou Ling,Wang Fei,Ma Tengfei,Ji Xinying,Yuan Ping,Liu Lin,Zhang Jianmin,Jia Wei,Duan Qiuhong,Zhu Feng
Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology
Reference42 articles.
1. Bastien, J. I., McNeill, K. A. & Fine, H. A. Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date. Cancer 121, 502–516 (2015).
2. Messaoudi, K., Clavreul, A. & Lagarce, F. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide. Drug Discov. Today 20, 899–905 (2015).
3. Verbeek, B., Southgate, T. D., Gilham, D. E. & Margison, G. P. O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy. Br. Med. Bull. 85, 17–33 (2008).
4. Neyns, B. et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann. Oncol. 20, 1596–1603 (2009).
5. Wang, A. L., Liu, Z. X., Li, G. & Zhang, L. W. Expression and significance of P53 protein and MDM-2 protein in human gliomas. Chin. Med. J. 124, 2530–2533 (2011).
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献